DEA Begins Issuing Medical Marijuana Registrations. Here’s What Businesses Need to Know.

 

The US has taken another small but important step toward recognizing state-licensed medical marijuana businesses. On October 30, 2026, the Department of Justice (DOJ) announced that the Drug Enforcement Administration (DEA) has begun issuing federal registrations to qualifying medical marijuana dispensaries.

The initial group includes more than 900 dispensaries in seven states: Alabama, Florida, Mississippi, South Dakota, Texas, Virginia, and West Virginia.

DEA also issued new guidance establishing a November 29, 2026 supply-chain compliance deadline for certain businesses. Here is what medical marijuana companies need to know.

Who Qualifies for Federal Registration?

As we previously reported, DOJ’s April 2026 rule placed certain state-authorized medical marijuana activities under Schedule III of the Controlled Substances Act (CSA). The rule established a federal registration pathway for qualifying medical marijuana manufacturers, distributors, and dispensaries.

However, a state medical marijuana license does not automatically confer federal registration. DEA must approve the application, and federal authorization cannot exceed the scope of the business’s state license. DEA has begun registering dispensaries and is reviewing applications from manufacturers and distributors.

What About Pending Applications?

Businesses that submitted complete DEA applications between April 28 and June 26, 2026 may qualify as “Timely Applicants.” Under the federal regulations, these businesses may generally continue covered medical marijuana activities while their applications remain pending, provided they maintain their state licenses and satisfy applicable conditions.

However, Timely Applicants generally may conduct Schedule III marijuana transactions only with other qualifying Timely Applicants or appropriately registered DEA businesses. Companies that applied after June 26 do not receive the same transitional authorization merely because their applications are pending. DEA maintains an updated list of Timely Applicants.

What About States with Both Medical and Recreational Marijuana?

Notably, none of the initial federal registrations went to businesses in states with operating recreational marijuana markets. Although Virginia has legalized adult possession, its licensed recreational market is not scheduled to open until July 2027. More importantly, DEA has taken the position that businesses operating under licenses authorizing both medical and recreational sales do not qualify for federal medical marijuana registration. In an October 30 order involving a Minnesota dispensary, DEA cited the state’s dual-purpose licensing system as grounds for denying registration. This creates a significant obstacle for medical marijuana businesses in states with combined programs, although it remains unclear whether businesses operating under separate medical-only licenses in those states may qualify. The issue could affect thousands of businesses that otherwise expected to benefit from Schedule III.

The November 29 Supply-Chain Deadline

In its October 30 guidance, DEA states that Timely Applicants are expected to verify their suppliers and customers and establish compliant supply chains by November 29, 2026.

For example, a qualifying dispensary generally cannot continue purchasing new medical marijuana inventory from a manufacturer that lacks both federal registration and Timely Applicant status. DEA warns that transactions with unqualified businesses may result in denial or revocation of federal registration. To be clear, the November 29 date is an agency compliance expectation, not a blanket grace period authorizing otherwise unlawful transactions.

What about existing inventory? DEA provides limited relief for Timely Dispenser and Distributor Applicants holding inventory acquired before October 30, including inventory obtained from suppliers that lack federal registration. However, the accommodation generally does not authorize additional purchases from those suppliers. Businesses should document existing inventory and verify their trading partners immediately.

Testing Laboratories Present Another Problem

State-licensed cannabis testing laboratories do not receive the same temporary federal authorization available to Timely Applicants. Recognizing the problem, DEA announced limited enforcement discretion allowing qualifying businesses to send small quantities of medical marijuana to unregistered in-state laboratories for required testing when appropriately registered laboratories are unavailable under specified conditions.

This is not a general exemption. DEA also states that unregistered laboratories cannot return marijuana to the businesses that submitted it. Companies should review their laboratory arrangements and determine whether their testing providers have the necessary federal authorizations.

Schedule III Does Not Mean Marijuana Is Federally Legal

The new framework has important limitations. The primary limitation is that adult-use marijuana remains a Schedule I substance. The April rule applies to specified medical marijuana activities and FDA-approved products, not the broader adult use/recreational market.

Federal registration also does not mean that marijuana products are FDA-approved or that interstate marijuana commerce is generally authorized.

Additionally, businesses remain subject to federal controlled-substance requirements, and registration does not guarantee access to banking services.

There may be significant tax benefits. Because Internal Revenue Code § 280E applies to Schedule I and II substances, qualifying Schedule III medical marijuana activities may no longer be subject to its deduction restrictions. However, businesses operating both medical and adult-use programs should obtain specific tax advice before changing their reporting practices.

What Businesses SHOULD Do Now

Medical marijuana companies should take the following steps:

1. Confirm federal status. Determine whether the company is DEA-registered, qualifies as a Timely Applicant, or needs to obtain federal registration.
2. Review suppliers and customers. Verify their DEA registration or Timely Applicant status before November 29. Maintain documentation.
3. Document existing inventory. Identify products acquired before October 30 that may qualify for DEA’s transitional accommodation.
4. Review testing arrangements. Confirm whether laboratories meet federal requirements or qualify under DEA’s narrow enforcement policy.
5. Update contracts and compliance procedures. Address federal registration status, inventory records, and the consequences if a trading partner loses its authorization.

Businesses should also evaluate how the changes affect their tax treatment, financial relationships, and existing operations.

My Take

DEA’s decision to begin registering medical marijuana businesses is a positive and long-overdue development. For decades, state-licensed operators have faced the contradiction of being authorized under state law while remaining prohibited under federal law. This change begins to address that problem. However, the new supply-chain restrictions could disrupt established businesses and potentially limit patient access. I continue to believe that Congress should remove cannabis from the Controlled Substances Act and establish reasonable federal standards that protect consumers while allowing legitimate businesses to operate and compete. Schedule III is progress, but it is far from being a substitute for comprehensive cannabis reform.

November 2, 2026